Treatment with propagermanium, a CCR2 inhibitor, for diabetic nephropathy

Treatment with propagermanium, a CCR2 inhibitor, for diabetic nephropathy - Treatment with propagermanium for diabetic nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004779

Enrollment

Registered

2011-01-04

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Control group Propagermanium group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Type 2 diabetes and its duration equal or longer than 5 years -Persistent microalbuminuria or proteinuria -Estimated GFR equal or greater than 30ml/min/1.73m2 -HbA1c < 10% -BMI 19-40 kg/m2

Exclusion criteria

Exclusion criteria: -Positive for hepatitis viral markers -Severe liver dysfunction -Past history of jaundice -Severe kidney dysfunction -Past history of arteriosclerosis obliterance, myocardial infarction or cerebral infarction within 3 month before enrollment -Age equal or older than 75 years

Design outcomes

Primary

Measure	Time frame
Urinary albumin excretion Urinary protein excretion	—

Secondary

Measure	Time frame
Blood pressure, kidney function, Blood glucose, HbAc1, lipid profile, White blood cells, high-sensitive CRP	—

Countries

Japan

Contacts

Public ContactTakashi Wada

Kanazawa University Department of Nephrology and Laboratory Medicine

lab-med@med.kanazawa-u.ac.jp076-265-2000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026